Fig. 5

Topical treatment with LIT-927 has no effect on HDM-induced airway inflammation but decreases respiratory symptom scores. Female C57/Bl6 mice (6–8 weeks old) were subjected to intranasal delivery of sterile PBS (10 µl) or house dust mite extract (HDM; 25 µg in 10 µl) 5 days a week for 5 consecutive weeks. At the end of the protocol, the lungs were removed and bronchoalveolar lavage (BAL) fluid was collected. A Schematic diagram of the schedule of allergen and drug delivery. B, C The orientation of the CXCL12 alone or CXCL12:LIT927 complex and the CXCR4. The receptor is depicted in ribbon format and colored N > C using rainbow coloring. The ligand is represented as a surface map and colored according to charge distribution. The circle highlights ligand penetration into the receptor core in either the undocked (CXCL12 only) or pre-docked (CXCL12:LIT-927) (B) the orientation of CXCL12 complex with CXCR4 (C) the orientation of the pre-docked CXCL12:LIT-927 complex with CXCR4. D Symptom scores were monitored throughout the 5-week protocol. Total inflammatory cell infiltrates were enumerated (E) and immune cell differentials (F–H) were determined using hematoxylin and eosin stained cytospin preparations of BAL fluid. n = 15 per group from two independent experiments; ***p < 0.001. HDM: house dust mite; LIT: LIT-927 (CXCL12 neutraligand); PBS: phosphate-buffered saline; VEH: vehicle control